NCT00119626

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,700 (planned)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.

Conditions

• Cerebral Stroke
• Ischemic Attack, Transient

Interventions

Type	Name	Description
DRUG	NXY-059

Timeline

• Start date: 2003-06-01
• Primary completion: 2005-02-01
• Completion: 2005-02-01
• First posted: 2005-07-14
• Last updated: 2010-11-15

Locations

2 sites across 2 countries: Sweden, United Kingdom